Total Voting Rights

RNS Number:0688D
BioProgress PLC
31 August 2007


For Immediate Release                                             31 August 2007



                BioProgress plc ('BioProgress' or the 'Company')

                     Total Voting Rights and Share Capital


London, UK, 31 August 2007: BioProgress (AIM: BPRG), the specialty pharma and 
healthcare company is required to notify the market of the following:

BioProgress' issued share capital consists of 192,709,433 ordinary shares with a
nominal value of 1 pence each, with voting rights. BioProgress does not hold any
ordinary shares in Treasury.

Therefore, the total number of voting rights in BioProgress is 192,709,433.

The above figure of 192,709,433 shares may be used by shareholders as the 
denominator for the calculations by which they will determine if they are
required  to notify their interest in, or a change to their interest in,
BioProgress  under the Financial Service Authority's Disclosure and Transparency
Rules.



For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
                                                                       
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                                    + 44 (0) 20 7466 5000
                                                                       
Rebecca Skye Dietrich
Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, the company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the United States as a launch mechanism for its own pharmaceutical products.
The business continues to develop innovative delivery mechanisms using its
XGEL(TM)polymer technology, replacing the need to use animal-derived gelatine in
pharmaceutical and healthcare products. For further information please go to
www.bioprogress.com


Forward-Looking Information

This announcement may contain forward-looking statements that reflect the
current views of BioProgress plc's management with respect to future events.
Forward-looking statements are based on current plans, estimates and
projections. You should consider them with caution. Such statements are subject
to risks and uncertainties, most of which are difficult to predict and are
generally beyond BioProgress plc's control. Detailed information about factors
pertinent to the business of the Company that could cause actual results to
differ is set forth in BioProgress plc's public reports and announcements, which
are published by the Regulatory News Service (RNS), the company news service of
the London Stock Exchange and on the Company's Web site (http://
www.bioprogress.com). If these or other risks and uncertainties materialize, or
if the assumptions underlying any of these statements prove incorrect,
BioProgress plc's actual results may be materially different from those
expressed or implied by such statements. The Company can offer no assurance that
its expectations or targets will be achieved. BioProgress plc does not assume
any obligation (and expressly disclaims any such obligation) to update
forward-looking statements to take new information or future events into account
or otherwise. This announcement is for information only and does not constitute
an offer or invitation to acquire or dispose of any securities, or investment
advice. The distribution of the announcement and/or issue of securities in
certain jurisdictions may be restricted by law. Persons into whose possession
this announcement comes are required to inform themselves about and to observe
such restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
TVRIIFFATTILVID